$13.38
Live
1.35%
Downside
Day's Volatility :8.97%
Upside
7.72%
56.28%
Downside
52 Weeks Volatility :77.82%
Upside
49.28%
Period | Cervomed Inc | Index (Russel 2000) |
---|---|---|
3 Months | -6.66% | 0.0% |
6 Months | -40.14% | 0.0% |
1 Year | 36.19% | 0.0% |
3 Years | 88.41% | -23.0% |
Market Capitalization | 116.0M |
Book Value | $6.06 |
Earnings Per Share (EPS) | 2.31 |
PE Ratio | 6.08 |
Wall Street Target Price | 57.6 |
Profit Margin | -52.24% |
Operating Margin TTM | -91.07% |
Return On Assets TTM | -90.48% |
Return On Equity TTM | 0.0% |
Revenue TTM | 9.7M |
Revenue Per Share TTM | 1.58 |
Quarterly Revenue Growth YOY | 91.2% |
Gross Profit TTM | 0.0 |
Diluted Eps TTM | 2.31 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.55 |
EPS Estimate Next Year | -2.54 |
EPS Estimate Current Quarter | -0.31 |
EPS Estimate Next Quarter | -0.45 |
What analysts predicted
Upside of 330.49%
Sell
Neutral
Buy
Cervomed Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Cervomed Inc | -8.33% | -40.14% | 36.19% | 88.41% | 88.41% |
Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Cervomed Inc | 6.08 | 6.08 | NA | -1.55 | 0.0 | -0.9 | NA | 6.06 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Cervomed Inc | Buy | $116.0M | 88.41% | 6.08 | -52.24% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Cervomed Inc
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 55.3%
diffusion pharmaceuticals is a clinical stage company focused on improving the effectiveness of standard-of-care therapies for life-threatening treatment-resistant solid cancerous tumors, without adding harmful side effects. the company is developing its lead drug, trans sodium crocetinate (tsc), which has received orphan drug designation from the fda for use in a number of cancers in which tumor hypoxia (oxygen deprivation) diminishes the efficacy of current treatments. tsc targets the cancer’s hypoxic micro-environment, re-oxygenating treatment-resistant tissue and making the cancerous cells more vulnerable to the therapeutic effects of conventional radiation and chemotherapy. the company is poised to begin a pivotal phase 3 trial in glioblastoma (gbm) in 2016. other programs include planned phase 2/3 trials in pancreatic cancer and brain metastases. because tsc’s novel mechanism safely re-oxygenates a wide range of tumor types, its use is not limited to a specific tumor tissue, but
Organization | Cervomed Inc |
Employees | 8 |
CEO | Dr. John J. Alam M.D. |
Industry | Miscellaneous |
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$13.38
-6.43%
Invesco Bulletshares 2025 Hi
$13.38
-6.43%
Schwab International Dividend Equity Etf
$13.38
-6.43%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$13.38
-6.43%
Lightpath Technologies Inc
$13.38
-6.43%
Vaneck Vectors Global Alternative Energy Etf
$13.38
-6.43%
First Trust Flexible Municipal High Income Etf
$13.38
-6.43%
Drx Dly Reg Bank Bull 3x
$13.38
-6.43%
Graniteshares 2x Long Pltr Daily Etf
$13.38
-6.43%